Shionogi & Co. has obtained a partial change to its manufacturing and marketing approval in Japan for its Omicron JN.1-lineage recombinant-protein COVID-19 vaccine, adding a booster dosage and administration regimen for use as additional immunization. The vaccine, developed under the code S-268024, uses a baculovirus-based protein-expression system paired with an adjuvant, a manufacturing approach long used in flu-vaccine production. It previously held separate Japanese approvals covering the original ancestral strain and the JN.1 strain on their own.
Shionogi says the three approvals together now complete the technical foundation for a vaccine platform intended to let it develop and supply shots matched to whichever strain Japan's authorities designate as the season's recommended vaccine, with reviews under that platform resting mainly on quality checks and preclinical data, premised on continued post-marketing data collection. The company is targeting completion of the platform during the fiscal year ending March 2027 and plans to pursue approval of a strain-matched vaccine under it.
The booster approved this week won't be part of that supply chain. It differs from the strain Japan has designated as the recommended vaccine for the 2026-2027 season, so Shionogi does not plan to supply it. The company said any financial effect from this approval is already reflected in its existing earnings forecast for the fiscal year ending March 2027. The payoff, in other words, is regulatory plumbing for next season's shot, not a product on shelves this one.